This month, FDA approval of mifepristone, a key drug used for medication abortion, has been the subject of several federal rulings. Representatives of the FDA and private drug companies have spoken out against the motion to overrule FDA approval, citing extensive safety data. Depending on the decision from the Supreme Court, these rulings could set a new precedent allowing federal courts to overturn FDA approval.
